Evidence map›Paper›PMID 23474986›Full record

ArticleNature2013

CLP1 links tRNA metabolism to progressive motor-neuron loss.

Toshikatsu Hanada, Stefan Weitzer, Barbara Mair, Christian Bernreuther, Brian J Wainger, Justin Ichida, Reiko Hanada, Michael Orthofer, Shane J Cronin, Vukoslav Komnenovic and 14 more

Abstract read
In one paragraph

Article in Nature, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 262 citations in OpenAlex.

  1. Article
  2. Enzymology of the metazoan tRNA ligase complex: a lifetime in cycles.Cellular and molecular life sciences : CMLS · 2026
    Review
  3. Article
  4. Article
  5. Unlocking the role of tRNA-derived fragments in shaping breast cancer signaling.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Emerging roles of transfer RNA fragments in the CNS.Brain : a journal of neurology · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 15 institutions in 5 countries.

Toshikatsu HanadaIMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna 1030, Austria.
Stefan Weitzer
Barbara Mair
Christian Bernreuther
Brian J Wainger
Justin Ichida
Reiko Hanada
Michael Orthofer
Shane J Cronin
Vukoslav Komnenovic
Adi Minis
Fuminori Sato
Hiromitsu Mimata
Akihiko Yoshimura
Ido Tamir
Johannes Rainer
Reinhard Kofler
Avraham Yaron
Kevin C Eggan
Clifford J Woolf
Markus Glatzel
Ruth Herbst
Javier Martinez
Josef M Penninger
Institute of Molecular Biotechnology · ATAustrian Academy of Sciences · ATOita University · JPUniversität Hamburg · DEWeizmann Institute of Science · ILBoston Children's Hospital · USBoston University · USCampus Science Support Facilities · ATHarvard Stem Cell Institute · USHarvard University · USHoward Hughes Medical Institute · USInnsbruck Medical University · ATKeio University · JPMedical University of Vienna · ATUniversität Innsbruck · AT

Funding

ALTERED SENSIBILITY FOLLOWING PERIPHERAL NERVE DAMAGER01NS038253 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI WOOLF, CLIFFORD J · 1999 to 2017
$8.2M
Conversion of Fibroblasts to fxnal Spinal Motor Neurons Using Defined FactorR00NS077435 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ICHIDA, JUSTIN KAWIKA · 2013 to 2015
$737k
Conversion of fibroblasts to functional spinal motor neurons using defined factorK99NS077435 · NINDS · HARVARD UNIVERSITY · PI ICHIDA, JUSTIN KAWIKA · 2011 to 2012
$177k
Austrian Science Fund FWF P 19223Austrian Science Fund FWF P 21667Howard Hughes Medical InstituteNINDS NIH HHS K99 NS077435NINDS NIH HHS K99NS077435-01A1NINDS NIH HHS NS038253NINDS NIH HHS R00 NS077435NINDS NIH HHS R01 NS038253
6 · The paper itself

Abstract

CLP1 was the first mammalian RNA kinase to be identified. However, determining its in vivo function has been elusive. Here we generated kinase-dead Clp1 (Clp1(K/K)) mice that show a progressive loss of spinal motor neurons associated with axonal degeneration in the peripheral nerves and denervation of neuromuscular junctions, resulting in impaired motor function, muscle weakness, paralysis and fatal respiratory failure. Transgenic rescue experiments show that CLP1 functions in motor neurons. Mechanistically, loss of CLP1 activity results in accumulation of a novel set of small RNA fragments, derived from aberrant processing of tyrosine pre-transfer RNA. These tRNA fragments sensitize cells to oxidative-stress-induced p53 (also known as TRP53) activation and p53-dependent cell death. Genetic inactivation of p53 rescues Clp1(K/K) mice from the motor neuron loss, muscle denervation and respiratory failure. Our experiments uncover a mechanistic link between tRNA processing, formation of a new RNA species and progressive loss of lower motor neurons regulated by p53.

Indexed as

Amyotrophic Lateral SclerosisAnimalsAnimals, NewbornAxonsCell DeathDiaphragmEmbryo LossEmbryo, MammalianExonsFemaleFibroblastsMaleMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicHexim1 protein, mouseRNA-Binding ProteinsRNA, Transfer, TyrTranscription FactorsTumor Suppressor Protein p53Tyrosine

Identifiers

PMID23474986
PMCPMC3674495
OpenAlexW2145067337

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.